Q-omics provides the consensus-scored TRIM56 profile across patient tissues and cancer cell-line models. TRIM56 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRIM56 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, TRIM56 RNA expression shows 20,508 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, LIHC, and ACC as cancer lineages where TRIM56 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM56 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM56 survival associations across molecular data types. TRIM56 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM56 RNA expression–survival associations across cancer types. High TRIM56 expression shows unfavorable associations in LGG and LIHC, but favorable associations in BLCA, SKCM, KIRC and STAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRIM56 RNA expression.
This table summarizes TRIM56 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM56. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM56 shows lower tumor expression in UCEC and higher tumor expression in LIHC, KIRC, STAD, KIRP and HNSC. The LIHC box plot shows higher TRIM56 RNA expression in tumor versus normal tissue (log2 FC = +1.395, t-test p < 0.001).
This table shows molecular features associated with TRIM56 in patient tissues and cancer cell lines. In patient samples, TRIM56 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM56 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
